Novo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to discover and develop RNA-blocking therapies for diseases such as NASH and ty
Merck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, vindicating a decision by the big US pharma to buy into the project for $1 billion.<
Roche has agreed to buy US biotech Promedior, and a portfolio of drugs including a promising molecule for the deadly lung-scarring disease idiopathic pulmonary fibrosis (IPF) in a deal wort
